Oruka Therapeutics, Inc.
About Oruka Therapeutics, Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $0
- Net income
- -$105.4M
- Total assets
- $488.6M
- Market cap
- $3.6B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $122.1M
- Operating income
- -$122.1M
- Net income
- -$105.4M
Balance sheet
- Total assets
- $488.6M
- Current assets
- $343.9M
- Total liabilities
- $16.7M
- Current liabilities
- $15.4M
- Shareholders’ equity
- $471.9M
Cash flow
- Operating cash flow
- -$88.2M
- Investing cash flow
- -$96.7M
- Financing cash flow
- $170.3M
- Net cash flow
- -$14.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.6B
- Shares outstanding
- 56.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 3, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $105.4M in FY2023.
- Trading 16% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Oruka Therapeutics, Inc..
Write a review
News about Oruka Therapeutics, Inc.
News & sentiment via Polygon.io
